You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
The company will use the proceeds to advance its lead BRAF inhibitor, PLX-8394, and develop new precision drugs using its FACT platform.
The company's approach combines whole-genome sequencing, CRISPR, liquid biopsy, and gene therapy to target cancer cells with gene fusions.
The company will use the funds to further develop its proprietary technology for identifying and isolating specific T-cell receptor genes from patients' tumor samples.
The company will use the proceeds to advance several biomarker-driven targeted drugs in its pipeline, including a recently licensed MDM2 inhibitor.
The company said proceeds will accelerate the ongoing FDA registrational study of its blood-based colorectal cancer screening test and further its extended pipeline.
The Chicago-based precision medicine software startup raised the funds through a Series A round led by digital health-focused venture capital firm HealthX Ventures.
Avatamed will use the funds to expand into the Asia-Pacific market and set up a lab in Singapore to provide precision cancer drug screening services.
The Seattle-based firm will use the funding to improve AI integration and further develop its Paris 3D tumor organoid diagnostic and drug discovery platform.
The Canadian company said its technology platform allows it to match patients to cancer treatments more efficiently and to identify novel patient populations.
The firm is using automated laboratory testing, artificial intelligence, and single-cell omics for a "precision" approach to cancer drug discovery.